Compare Innovative Industrial Properties Inc (IIPR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Innovative Industrial Properties Inc trades at $51.47 (market cap $1.42B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Innovative Industrial Properties Inc is the larger of the two by market cap, and Innovative Industrial Properties Inc pays a 14.74% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 87 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IIPR | MRVI | |
|---|---|---|
Market Cap | $1.42B | $972.90M |
Volume | 427,967 | 4,325,710 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $9.00 |
52-Week Low | $44.58 | $2.83 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $1.95B | $1.08B |
Dividend Yield | 14.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.43, up 0.47% on the day, exhibiting a bearish technical trend near key support at $51. Fundamentally, the REIT shows high gross margins of 88.35% but faces revenue and net income declines in 2025. Recent news highlights a significant $245 million mezzanine loan commitment, signaling active capital deployment despite sector headwinds.
The outlook is mixed; the stock offers a high dividend yield but carries risks from tenant defaults and volatile earnings. Analyst consensus is cautious with a majority Hold rating. Investors should weigh the attractive valuation metrics against operational challenges in the cannabis real estate sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
